Evaluation of telephone and virtual visits for routine pediatric diabetes care during the COVID-19 pandemic

Alex Fung a, Mike Irvine b, Aysha Ayub a, Shabnam Ziabakhsh c, Shazhan Amed a, Brenden E. Hursh a, c

a Division of Endocrinology, Department of Pediatrics, British Columbia Children’s Hospital and University of British Columbia, 4480 Oak St., Vancouver, BC V6H 3V4, Canada
b Biostatistics Core, Clinical Research Support Unit, BC Children’s Research Institute, 938 W 28th Ave, Vancouver, BC V5Z 4H4, Canada
c BC Women’s Hospital and Health Centre, Women’s Health Research Institute, 4500 Oak Street, Vancouver, BC V6H 3N1, Canada

ARTICLE INFO

Keywords: Diabetes mellitus, type 1 Pediatrics Insulin pump therapy Continuous glucose monitor COVID-19 Telehealth

ABSTRACT

Aim: To evaluate pediatric type 1 diabetes telehealth visits during the COVID-19 pandemic, with a focus on assessing the usability of these visits and gathering patient perspectives.

Methods: An online survey, which included a validated telehealth usability questionnaire, was offered via email to families with a telephone or virtual visit since the COVID-19-related cancellation of routine in-person care. Survey data was linked with the British Columbia (BC) Clinical Diabetes Registry. Outcomes between groups were assessed using Welch’s t-test. Associations with type of visit as well as with desire to return to in-person care were assessed with logistic regression models.

Results: The response rate was 47%. Of 141 survey respondents, 87 had clinical data available in the BC Clinical Diabetes Registry, and thus were included in our analysis. Overall, telephone and virtual visits were rated highly for usability. Telephone visits were easier to learn to use, and simpler to understand; however, telephone and virtual visits were similar across multiple areas. No factors associated with choosing one type of visit over the other, or with desire to return to in-person care, could be identified. 72% of participants want future telehealth care; however, some would like all future care to be in-person.

Conclusions: Telephone and virtual visits had impressive usability. Many families want telehealth to play a significant part in their future care.

Introduction

In British Columbia (BC), more than 2000 children and adolescents have type 1 diabetes mellitus (T1D), a serious disease that requires intensive daily medical management. Pediatric diabetes has remained primarily an ‘in-person’ specialty across Canada, and in line with that, the diabetes team at BC Children’s Hospital (BCCCH) sees more than 1400 in-person pediatric diabetes visits per year. Up until now, only a small proportion of patients at BCCCH were seen by virtual care, and this service was limited to patients living far away from our hospital. These visits accounted for approximately 5% of all visits, and only 1 out of 8 physicians in the division participated in virtual health prior to the novel coronavirus (COVID-19) pandemic. During the early stages of the COVID-19 pandemic, and in line with provincial health mandates, the diabetes team rapidly shifted to performing 100% of routine diabetes clinic visits by either telephone or virtual technology.

Recent work has revealed that healthcare professionals have been observing an increased incidence of diabetic ketoacidosis in youth [1-3], possibly attributed to parents avoiding hospital visits due to the concern of potential infection with COVID-19 [3]. Similarly, for individuals living with diabetes, the COVID-19 pandemic is correlated with increased variability in glycemic control and a reduction in physical activity [4], which may be a result of stay-at-home recommendations. However, the International Society of Pediatric and Adolescent Diabetes (ISPAD) has highlighted both a critical need for continued diligence in providing standard pediatric diabetes care to avoid health complications and hospitalizations, as well as the importance of ongoing collaboration between patients, families and healthcare providers [5].

https://doi.org/10.1016/j.jcte.2020.100238
Received 21 August 2020; Received in revised form 28 September 2020; Accepted 3 October 2020
ISPAD has reported a swift increase in utilization of telehealth as a strategy for healthcare professionals to continue to provide care for children and adolescents with diabetes [5], and this transition from in-person visits to virtual health technologies during COVID-19 seems to be a global trend [1].

Despite the recent rapid uptake of virtual care in the setting of the COVID-19 pandemic, there are no long-term studies describing virtual health services for pediatric diabetes [6]. The use of virtual care in young adults aged 18–25 has demonstrated that telehealth keeps patients engaged in their diabetes care, increases treatment adherence and is overall feasible and acceptable in this population [6,7]. In the pediatric age range, it has been reported that telehealth increases access to healthcare and may improve overall diabetes care [8,9]. Of specific interest to our study team in the current context of the rapid shift to virtual care during the pandemic, is the concept of usability. Usability refers to the extent to which a product is used “to achieve specified goals with effectiveness, efficiency and satisfaction in a specified context” [10]. Usability has been identified as an enabler of successful telehealth care, and may reduce burden on patients and clinicians [11]; however, there remains limited information about the usability of virtual technologies for pediatric patients and their families, especially during a pandemic.

As there has been an unprecedented and rapid shift to a new model of diabetes care delivery, we set out to understand these visits from the patient’s perspective. The objectives of this study were to evaluate the usability of diabetes telephone and virtual visits and to identify any differences in usability between these two modes of care. We also set out to describe patient characteristics that might predict a preference for virtual versus telephone visits. Finally, in the setting of this rapidly imposed change in care delivery, we sought patient feedback regarding inclusion of telephone and virtual care in their future visits.

Subjects, materials and methods

Context

BC Children’s Hospital is the sole tertiary children’s hospital serving British Columbia, Canada. The program has a provincial mandate, and accordingly, the diabetes program serves approximately 900 children with diabetes from across BC. Prior to the COVID-19 pandemic, most patients were seen approximately 1–3 times per year for in-person visits with a multidisciplinary diabetes team. As a result of the COVID-19 pandemic, starting on March 25, 2020 all in-person routine diabetes visits were cancelled, and, in their place, families were provided the opportunity to self-select into either a telephone (audio only) or virtual (video and audio using Skype for Business or Zoom) visit. For telephone visits, the families had a pre-scheduled time for a 30-minute call. For virtual visits, families received an email link for their pre-scheduled 30-minute visit using a computer or smartphone. Prior to each telephone or virtual visit, a diabetes nurse educator contacted the family and encouraged them to send in blood glucose and insulin dose information by email and to upload any diabetes technology data (i.e. pump and/or continuous glucose monitor (CGM)). The nurse also provided connection information for families not linked with our clinic accounts. Files that were received or available in advance of the visit were then printed and available for the clinicians to use during the clinic visit.

Study design

A cross-sectional telehealth usability and feedback questionnaire was offered to all families who had a recent telephone or virtual diabetes visit from March 25 to May 27, 2020, and for whom there was an email address available. Based on this inclusion criteria, 301 patient families were identified to be eligible for the study and were invited to participate in the questionnaire via an online link. Survey data were collected from May 28 – June 9, 2020.

Questionnaire

The survey was designed and pilot tested by an interdisciplinary team of pediatric endocrinologists, diabetes nurse- and dietitian-educators, endocrinology trainees and diabetes administrative staff. Our survey instrument was also pilot tested with two people living with T1D for comprehension and ease of completion. Their comments resulted in changes to survey language resulting in increased clarity and readability. The survey consisted of the Telehealth Usability Questionnaire, modified to the current context of telephone and virtual visits. The Telehealth Usability Questionnaire (TUQ) is a validated tool that was designed to assess the delivery of virtual health care. The TUQ addresses multiple aspects of usability: usefulness, ease of use, interface quality, interaction quality, reliability and satisfaction and future use. It was developed with newer-generation virtual care platforms in mind, such as those used by our diabetes team during the COVID-19 pandemic, and it combines items from existing telehealth questionnaires. Questions in the TUQ can be tailored to address participants and virtual health systems in different settings. The TUQ has strong content validity, reliability and it has been noted to be a solid, robust and versatile measure [12]. Of the validated 21-question TUQ, 4 questions for the telephone group and 3 questions for the virtual group were removed as they did not apply in our context. No questions were altered in intention or meaning. Several additional questions were developed for this study to assess the visit characteristics (5 questions) and preferences for future care (6 questions), and these questions were analyzed separately from the TUQ questions. A 4-point Likert scale was used, with response categories of “Not at all/Partly/Quite a bit/Completely”, similar to the scale used in the pan-Canadian patient survey [13]. The questionnaire is included as a supplementary file.

Study participants and recruitment

Families who had a telephone or virtual diabetes visit from March 25 to May 27, 2020, and for whom there was an email address available, were eligible and were introduced to the study by email. They were provided study information and the opportunity to consent to both survey participation and linkage of clinical information (such as age, sex, time since diagnosis, insulin pump use, CGM use and insulin regimen) with survey results. The introductory email contained a link to complete the survey online. In addition to the initial email, families received a series of 3 automated email reminders over the course of the data collection period.

Data collection and management

All families completed the survey via an online database platform, Research Electronic Data Capture (REDCap). REDCap is a secure, web-based application designed to support data capture for Quality Improvement/Quality Assurance (QI/QA) and research studies. REDCap was used to build and administer the survey as well as store survey data. The BCCH diabetes program follows 890 pediatric patients with T1D or type 2 diabetes mellitus (T2D). Many of these patients (542/890, 61%) have provided consent to participate in the BC Pediatric Diabetes Registry, a clinical registry that collects de-identified patient-level (e.g. demographic data, diabetes type, co-morbidities, etc.) and visit-level data (e.g. glycated hemoglobin (HbA1c), insulin pump use, CGM use, etc.) for the purpose of supporting quality improvement research. While all patient families with a recent telephone or virtual diabetes visit were invited to participate in the survey, our analysis included only those who were also in the clinical registry, as this allowed for exploration of associations between survey results and clinical characteristics.

Data analysis

The number of visits within the study period and an anticipated
A. Fung et al.

Table 1
Characteristics of survey participants and all patients enrolled in the BC Pediatric Diabetes Registry.

| Characteristic                        | Survey participants | All patients |
|---------------------------------------|---------------------|--------------|
|                                       | Telephone n = 47    | Overall n = 87 | n = 542      |
| Age (years), mean (SD)                | 13.2 (4.3)          | 12.8 (4.3)   | 13.2 (4.2)   |
| Time since diagnosis (years), mean (SD)| 7.1 (4.6)          | 6.7 (4.3)    | 6.1 (4.1)    |
| Most recent HbA1c, mean % (mmol/mol)  | 7.9 (0.3)           | 7.9 (0.3)    | 8.0 (0.4)    |
| Mean (SD)                             | 7.9 (3.7)           | 7.9 (1.9)    | 8.0 (1.6)    |
| Sex, n (%)                            | 22 (46.8)           | 37 (42.5)    | 248 (45.8)   |
| Type of diabetes, n (%)               |                     |              |              |
| Type 1 diabetes                       | 12 (30.0)           | 24 (27.6)    | 20 (36.0)    |
| Type 2 diabetes                       | 12 (30.0)           | 28 (32.2)    | 14 (25.4)    |
| Distance from center (km), n (%)      |                     |              |              |
| <10                                   | 12 (25.5)           | 24 (27.6)    | 26 (47.8)    |
| 10–24.9                               | 16 (34.0)           | 28 (32.2)    | 27 (49.1)    |
| 25–99.9                               | 15 (31.9)           | 24 (27.6)    | 24 (44.4)    |
| 100–200                               | 1 (2.1)             | 2 (2.3)      | 3 (5.6)      |
| >200                                  | 3 (6.4)             | 9 (10.3)     | 7 (12.9)     |
| Currently using CGM, n (%)            | 24 (51.1)           | 49 (56.3)    | 194 (35.8)   |
| Number of SMBG per day (if not using CGM), mean (SD) | 5.3 (3.0) | 4.2 (0.9) | 5.1 (2.6) |
| Type of insulin regimen, n (%)        |                     |              |              |
| Insulin pump                          | 21 (44.7)           | 44 (50.6)    | 229 (42.3)   |
| Multiple daily injections             | 18 (38.3)           | 29 (33.3)    | 176 (32.5)   |
| Conventional insulin                  | 6 (12.6)            | 12 (13.8)    | 123 (22.7)   |
| Basal insulin only                    | 1 (2.1)             | 1 (1.1)      | 5 (0.9)      |
| No insulin                            | 1 (2.1)             | 1 (1.1)      | 9 (1.7)      |
| Who attended the visit, n (%)         |                      |              |              |
| Child only¹                           | 3 (6.4)             | 4 (4.6)      | –            |
| Parent(s)/family member(s)/guardian(s) only | 14 (29.8) | 17 (19.5) | –            |
| Both parent(s)/family member(s)/guardian(s) and child | 30 (63.8) | 66 (72.9) | –            |
| Who filled out the survey, n (%)      | 38 (80.9)           | 69 (79.3)    | –            |
| A child or teen with diabetes         | 4 (8.5)             | 5 (5.7)      | –            |
| A parent/family member/guardian       | 5 (10.6)            | 13 (14.9)    | –            |
| Both a parent/family member/guardian and a child or teen with diabetes together | 8 (20.0) | 13 (14.9) | –            |

¹ Patient ages: 15.9, 17.2, 18.2 and 18.5 years. HbA1c, glycated hemoglobin; SD, standard deviation; SMBG, self-monitoring of blood glucose; CGM, continuous glucose monitor.

Results

Survey response

Out of 301 eligible patient families that were invited via email to participate in the survey, we received 141 completed responses, resulting in a 47% response rate. There were 4 respondents in the telephone care group and 2 respondents in the virtual care group who started but did not complete the survey, and thus were omitted from our analysis. Eighty-seven of the 141 respondents that completed the survey had previously provided consent for their clinical data to be linked via telephone care group and virtual care groups were similar in age, time since diagnosis, HbA1c, sex and distance from their diabetes center. Although not statistically significant, there was a higher proportion of pump therapy (57.5% vs 44.7%, \( P = 0.2 \)) and CGM use (62.5% vs 51.1%, \( P = 0.3 \)) among families who chose to have their visit by virtual care, compared to the telephone care. We performed a regression analysis to look for associations between patient factors and the choice of visit type.

Response rate of 30% determined the sample size. All participants who completed the survey and who had provided consent to be part of the clinical registry were included in the analysis. Results from the Likert scale were presented in the form of median, interquartile range and percentages as these were found to best describe the central tendency and spread of the data. Tests for statistical significance of outcomes between telephone care and virtual care groups were assessed using Welch’s t-test (two-sample assuming unequal variances). The use of t-tests is justified as assumptions of normality of the sample mean have been shown to be robust when applied to Likert scales [14]. Statistical significance was set at \( P < 0.05 \). To understand the associations between patient factors and choosing a virtual visit as well as preference to return to all in-person visits, we performed a series of logistic regression models on the outcome of choosing a virtual visit and the outcome of selecting preference for a return to all in-person visits. For both outcomes the following predictors were applied: age at visit, sex, time since diagnosis, pump use, CGM use, HbA1c and distance from BCCH. Both unadjusted and adjusted odds ratios were estimated based on univariable and multivariable logistic regressions. Finally, to compare characteristics of survey respondents to the larger BCCH clinic population, data is presented for available metrics for all patients with T1D or T2D who are participating in the clinical registry. Microsoft Excel 2020™, R version 3.0.1 and SPSS Version 27 were used for analyses.

Research ethics

Approval for the administration of this quality improvement survey was granted by the Research Privacy Advisor (Provincial Health Services Authority), which is the requirement for quality improvement studies at our institution. This study was conducted for quality improvement and monitoring and, therefore, did not fall under the scope of the Research Ethics Board, as per the University of British Columbia Guidance notes, Article 4.4.1 and Tri-Council Policy Statement 2 (TCPS2) Article 2.5 [15,16]. However, consent was gathered at the time of survey administration, and participants were informed that they could withdraw their consent at any time. Data collection occurred in accordance with the agency’s privacy laws. This proposal meets R Project Ethics Community Consensus Initiative (ARECCI) Ethics Screening Tool criteria for Quality Improvement and Evaluation projects [17].
much higher for the virtual care group compared to the telephone group. Occasionally there was no significant odds ratios in both the unadjusted and adjusted analysis for both outcomes, although 95% confidence intervals were wide indicating the current study is underpowered to detect an effect (e.g. pump use has an odds ratio of 1.68–4.97) for opting for a virtual visit.

A comparison between study participants and the diabetes registry with respect to age, sex, type of diabetes, HbA1c, pump use and CGM use are also included in Table 1. Overall, the characteristics of the survey respondents were similar to the larger group; however, it is noteworthy that participants of the study, when compared to the greater clinic population, reported higher pump use (50.6% vs 42.3%, P = 0.1) and statistically higher CGM use (56.3% vs 35.8%, P = 0.001).

### The visit

In place of in-person routine diabetes visits, families were called by our administrative staff and offered the option to self-select into either a telephone (audio only) or virtual (video and audio using Skype for Business or Zoom) visit. For telephone visits, the families had a pre-scheduled time for a 30-minute call. For virtual visits, families received an email link for their pre-scheduled 30-minute visit using a computer or smartphone. Information about which family members attended the visits is presented in Table 1, which shows a comparison between the telephone and virtual care groups. Of the 87 complete responses that were included in the current analysis, 47 and 40 responses were from the telephone and virtual care groups, respectively. The proportion of visits including both a family member and the child was much higher for the virtual care group compared to the telephone group. A diabetes doctor attended nearly all visits, while families also reported that a diabetes nurse attended less frequently. Occasionally there was the presence of a dietitian, social worker, medical trainee or other physician.

### Usability

Overall, across the usability survey components of usefulness, ease of use and learnability, interface quality, interaction quality and satisfaction and future use, all had median scores for both telephone visits and virtual visits of “quite a bit” or “completely”, while the scores for reliability for both groups was “partly” (Table 2). The distribution of responses for both groups across the 6 usability components is presented in Fig. 1. Responses to the individual items on the TUQ generally mirrored those observed from the usability component scores and are outlined in Table 2. In terms of usefulness, although families believe that a telephone or virtual visit “completely” saves them travel time and “completely” provides for their healthcare needs, they express that the visit only “partly” improves their access to healthcare services. In terms of ease of use and learnability, families reported that the telephone or virtual systems were “completely” simple to use and “completely” easy to learn, although a between-group comparison revealed that the telephone group found it easier to learn the system for the visit than the virtual group (P = 0.005). Overall, usefulness favoured the telephone group (P = 0.005). In terms of interface quality, this also favored the telephone group (P = 0.013); however, both groups had the same median score of “partly” across all items. Families reported slightly lower scores for individual questions in both the reliability and satisfaction and future use components. A median score of “partly” was recorded for their perspective on whether the visit was the

---

**Table 2**

| Usability Component and Questionnaire Items | Telephone Care | Virtual Care | Overall | P value |
|--------------------------------------------|----------------|--------------|---------|---------|
| **Usefulness**                             |                |              |         |         |
| A telephone/virtual visit improves my access to healthcare services | 3 (2–4) | 3 (2–4) | 3 (2–4) | –       |
| A telephone/virtual visit saves me time traveling to a hospital or specialist clinic | 2 (2–3) | 2 (2–3) | 2 (2–3) | –       |
| A telephone/virtual visit provides for my healthcare needs | 3 (2–4) | 3 (2–4) | 3 (2–4) | –       |
| **Ease of Use and Learnability**           |                |              |         |         |
| It was simple to use this telephone/virtual system | 4 (3–4) | 3 (2–4) | 4 (3–4) | 0.005   |
| It was easy to learn to use the system | 4 (3–4) | 3 (2–4) | 4 (3–4) | –       |
| **Interface Quality**                      |                |              |         |         |
| The way I interact with this telephone/virtual system is pleasant | 3 (3–4) | 3 (2–4) | 3 (2–4) | 0.013   |
| I like using the system | 3 (3–4) | 3 (2–4) | 3 (2–4) | –       |
| The system is simple and easy to understand | 3 (3–4) | 3 (2–4) | 3 (2–4) | –       |
| This system is able to do everything I would want it to be able to do | 3 (2–4) | 3 (2–4) | 3 (2–4) | –       |
| **Interaction Quality**                    |                |              |         |         |
| I could easily talk to the clinician | 3 (3–4) | 3.5 (3–4) | 3 (3–4) | –       |
| I could hear the clinician clearly | 4 (3–4) | 4 (3–4) | 4 (3–4) | –       |
| I felt I was able to express myself effectively | 3 (3–4) | 4 (3–4) | 4 (3–4) | –       |
| I could see the clinician as well as if we met in person | – | 3 (2–4) | 3 (2–4) | –       |
| **Reliability**                            |                |              |         |         |
| I think visits provided this way are the same as in-person visits | 2 (1–3) | 2 (1–3) | 2 (1–3) | –       |
| **Satisfaction and Future Use**            |                |              |         |         |
| I felt comfortable communicating with the clinician during this visit | 3 (2–4) | 3 (2–4) | 3 (2–4) | –       |
| The visit was an acceptable way to receive healthcare services | 2 (2–3) | 2 (2–3) | 2 (2–3) | –       |
| I would use these services again | 2 (2–3) | 2 (2–3) | 2 (2–3) | –       |
| Overall, I am satisfied with this type of visit | 3 (2–4) | 3 (2–4) | 3 (2–4) | –       |
| **Overall Usability (all items)**          | 3 (2–4) | 3 (2–4) | 3 (2–4) | –       |

(virtual or telephone) as well as preference for returning to in-person visits in the future. There were no significant odds ratios in both the unadjusted and adjusted analysis for both outcomes, although 95% confidence intervals were wide indicating the current study is underpowered to detect an effect (e.g. pump use has an odds ratio of 1.68 (95% CI: 0.72 – 3.97)) for opting for a virtual visit.
same as in-person visits, if the visit was an acceptable way to receive healthcare services, and if they would use this service again. However, a higher score of ‘quite a bit’ was reported for families’ comfort in communicating with the clinician during the visit, and their overall satisfaction with the visit.

Preferences for future telephone and virtual diabetes care

A number of questions were designed to gain insight on family preferences for future telephone and virtual diabetes visits (Table 3). There were no notable differences in responses to these questions between the telephone versus virtual care group. For future telephone and virtual visits, almost all families would like the diabetes doctor to be involved, and many would like other members of the multidisciplinary team involved. Families were asked if they would, once the COVID-19 pandemic resolves, still like to continue to receive telephone or virtual visits as part of their diabetes care. Three-quarters of families would like telephone or virtual visits to be included in their future care, while about one-quarter of families would prefer all of their future visits to be in-person. A regression analysis was conducted to look for associations between patient factors and the desire to have all in-person future care. No significant associations were found between potential predictors and in-person care although confidence intervals were wide for some predictors indicating a lack of power with the current sample to identify these associations.

When given the prompt that clinical practice guidelines suggest children with diabetes should have 4 diabetes-related visits per year [18], most families (58.6%) agreed with this frequency, while 18.4%, 21.8%, and 1.1% of families overall would like only 3, 2, and 1 visit per year with our team, respectively, for a mean (SD) of 3.3 (0.9) visits per year. Families were also asked, out of their total number of diabetes visits per year, how many in-person and telephone/virtual visits they would like to have per year. The majority of families (61.6%) would like to have 2 in-person visits per year [mean (SD): 2.1 (0.9)]. A similar proportion of families (57.9%) would also like to have 2 telephone/virtual visits per year [mean (SD): 1.7 (0.8)]. There were no statistically significant differences in the responses to these questions between the telephone care and virtual care groups.

Discussion

To our knowledge, this is the first study to report on a tertiary diabetes centre’s complete transition to telephone and virtual care for pediatric diabetes during the COVID-19 pandemic. As the only tertiary children’s hospital in BC, our program was afforded the opportunity to gain insight from a large number of clinical encounters in a short timeframe during the early stages of the COVID-19 pandemic.

At our centre, when families were able to self-select a telephone or virtual care visit, the overall assessment of the visits by families is positive. The telephone visits were deemed easier to learn to use, and more simple and easy to understand, but overall the ratings of telephone and virtual visits by families were similar across multiple areas on the TUQ. It is interesting that univariate and multivariate modeling revealed no clear patient-related factors associated with families choosing one type of visit over the other. Furthermore, it stands out strongly that while most participants said that they would like to have more telephone or virtual visits in the future, nearly one quarter of families would like all future care to be in-person. It is essential that we work to identify which families are not compatible with telephone or virtual health visits, so that we may continue to strive for equitable and family-centered care across the province for all. Furthermore, some initial assumptions were not born out in this study: it was not the tech savvy (pump or CGM users) who necessarily chose virtual visits, nor did distance from the diabetes clinic associate with preference for in-person or remote visits. Clearly, we must become more refined in our ability to understand which families will benefit most, or potentially be harmed the most, from a transition to telephone or virtual care.

Our clinic practices family-based care, and accordingly in-person visits are attended by the child/teen and parents/guardians. It is interesting that in the telephone and virtual setting, we notice some visits occurring with the parent/guardian only and no child (19.5%), and a few visits with older teens only and no parent/guardian (4.6%). A much higher proportion of virtual visits had attendance by both child and parent (90%), compared to telephone visits (63.8%). This is interesting for clinicians to consider when scheduling remote visits with families: virtual care, as opposed to telephone care, may facilitate a greater chance of the child participating in the visit and engaging with their own chronic disease management. This is consistent with previous findings that have demonstrated virtual visits facilitate increased engagement and patient and parent involvement in their diabetes care [7,19]. Additionally, in children and adolescents with T1D, parental care and involvement have been shown to have a positive impact on the patient’s diabetes management [20], which further supports the need to keep families engaged and in close communication with the healthcare team. In times of a pandemic, telehealth is a means to achieve this goal, and we have shown telephone and virtual visits to have good usability and to be well received by most families. In terms of future visits, many families have a desire for a multidisciplinary approach to phone and
incorporate in future care. We will transition into a longer-term model of care that, while retaining the benefits of virtual care, will be adaptable to new standards of care in diabetes practice in the setting of a novel pandemic. A limitation is that the perspectives collected are of those who self-selected to participate in the survey, which may introduce responder bias in the dataset. A higher percentage of people were using insulin pump therapy and/or CGM in the survey respondents, when compared to the entire diabetes clinical database group. It is possible that families with more technologically advanced diabetes care may have been more likely to respond to an email request for an online survey. Additionally, this study did not capture the perspectives of the healthcare professionals taking part in these visits. In order to further understand the usability of the telephone and virtual systems in the setting of the current pandemic, this additional group should be considered. Notably, healthcare professionals recently identified a number of benefits in using video consultations for routine pediatric diabetes visits. Additionally, future research should gather more in-depth perspectives through qualitative interviews with patient families and healthcare professionals, which will provide further insight on which families would benefit most and least from telehealth for their diabetes care. Follow-up work will also need to assess for the attainment of standards of care in diabetes practice in the setting of a novel model of routine diabetes care delivery.

Conclusion

We provide the first report on a tertiary diabetes centre’s complete transition to telephone and virtual care for routine pediatric diabetes visits during the COVID-19 pandemic. In this setting, where families chose their preferred visit type, both telephone and virtual care visits had impressive usability. A flexible offering of care delivery options should be considered as a potentially helpful approach to providing telehealth care. Furthermore, factors differentiating between families who prefer different styles of telehealth care need to be further delineated. We must strive to understand more about the groups who do, and do not, thrive within a telehealth care setting. This study provides an initial roadmap for how our families wish to see care provided in the future, which appears to be a flexible blend of in-person and telehealth visits, with the option of having a multidisciplinary team participating in the visits. Insights from this study are already informing improved care in the setting of the pandemic within our program. Ongoing assessment

Table 3

| Visit Type                        | Telephone n (%) | Virtual n (%) | Overall n (%) |
|-----------------------------------|-----------------|---------------|---------------|
| **Which diabetes team members would you like to have involved in future telehealth visits?** |                 |               |               |
| Diabetes doctor                   | 45 (95.7)       | 37 (92.5)     | 82 (94.3)     |
| Diabetes nurse                    | 27 (57.4)       | 24 (60.0)     | 51 (58.6)     |
| Diabetes dietitian                | 16 (34.0)       | 13 (32.5)     | 29 (33.3)     |
| Social Worker                     | 5 (10.6)        | 2 (5.0)       | 7 (8.0)       |
| Other health care provider(s) not from BCCH | 0 (0.0)    | 1 (2.5)       | 1 (1.1)       |
| Other: translator                 | 0 (0.0)         | 1 (2.5)       | 1 (1.1)       |
| After COVID-19, would you like telehealth visits continued as a way for you to receive care from your diabetes team? |                 |               |               |
| Yes, in place of all of my visits with the BCCH diabetes team | 1 (2.1) | 0 (0.0) | 1 (1.1) |
| No, I would prefer all of my visits to be in person | 12 (25.5) | 9 (22.5) | 21 (25.5) |
| Unsure | 3 (6.4) | 0 (0.0) | 3 (3.4) |
| If you could have a combination of in-person and telehealth visits, in a full year how many diabetes related visits in total would you like to have with BCCH? |                 |               |               |
| 1 visit/year                      | 1 (2.1)         | 0 (0.0)       | 1 (1.1)       |
| 2 visits/year                     | 13 (27.7)       | 6 (15.0)      | 19 (21.8)     |
| 3 visits/year                     | 8 (17.0)        | 8 (20.0)      | 16 (18.4)     |
| 4 visits/year                     | 25 (53.2)       | 26 (65.0)     | 51 (58.6)     |
| Preferred total number of visits per year, mean (SD) | 3.2 (0.9) | 3.5 (6.5) | 3.3 (58.6) |
| In a full year, how many in-person and telephone/virtual visits would you like to have with our diabetes team? |                 |               |               |
| In-person visits per year         |                 |               |               |
| 0 visits/year                     | 0 (0.0)         | 0 (0.0)       | 0 (0.0)       |
| 1 visit/year                      | 8 (17.4)        | 8 (20.0)      | 16 (18.6)     |
| 2 visits/year                     | 30 (65.2)       | 23 (57.5)     | 53 (61.6)     |
| 3 visits/year                     | 5 (10.9)        | 1 (2.5)       | 6 (7.0)       |
| 4 visits/year                     | 3 (6.5)         | 8 (20.0)      | 11 (12.8)     |
| Preferred number of in-person visits per year, mean (SD) | 2.1 (0.7) | 2.2 (1.0) | 2.1 (0.9) |
| Telephone/virtual visits per year |                 |               |               |
| 0 visits/year                     | 1 (2.3)         | 5 (13.2)      | 6 (7.5)       |
| 1 visit/year                      | 13 (29.5)       | 11 (28.9)     | 24 (29.3)     |
| 2 visits/year                     | 27 (61.4)       | 20 (52.6)     | 47 (57.3)     |
| 3 visits/year                     | 2 (4.5)         | 1 (2.6)       | 3 (3.7)       |
| 4 visits/year                     | 1 (2.3)         | 1 (2.6)       | 2 (2.4)       |
| Preferred number of telephone/virtual visits per year, mean (SD) | 1.8 (0.7) | 1.5 (0.9) | 1.7 (0.8) |

BCCH, BC Children’s Hospital; SD, Standard deviation.
of care provision in the setting of the COVID-19 pandemic, and associated adaptation in care delivery, is essential in a time of such dramatic change.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank the families who participated in the survey, as well as the people who participated in survey review and development. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

AF, BH, MI, SA and SZ contributed to study design. AF and BH administered the survey. AA assisted with data collection and data linkage. AF, BH and MI performed data analysis. AF and BH prepared the manuscript. All authors participated in manuscript review and have approved the final version.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jetc.2020.100238.

References

[1] N.S. Elbarbary, T.J. dos Santos, C. de Beaufort, J.C. Agwu, L.E. Calliari, A.E. Scaramuzza, COVID-19 outbreak and pediatric diabetes: perceptions of health care professionals worldwide, Pediatric Diabetes, p. pedi.13084, Jul, 2020, doi: 10.1111/pedi.13084.
[2] Ho C, Ng NBH, Lee YS. Caring for pediatric patients with diabetes amidst the coronavirus disease 2019 storm. J. Pediatrics 2020;225:186–7. https://doi.org/10.1016/j.jpeds.2020.04.067.
[3] Dayal D, Gupta S, Raithatha D, Jayashree M. Missing during COVID-19 lockdown: Children with onset of type 1 diabetes. Acta Paediatr. 2020;109(10):2144–6. https://doi.org/10.1111/apa.15443.
[4] Barone MTU, Harmik SB, de Luca PV, Lima BlaDS, Wieselberg RJP, Ngongo B, Pedroso HC, Pimazoni-Netto A, Franco DR, Marinbo de Souza MdF, Malta DC, Giampaoli V. The impact of COVID-19 on people with diabetes in Brazil. Diabetes Res. Clin. Pract. 2020;166:108304. https://doi.org/10.1016/j.diabres.2020.108304.
[5] International Society of Pediatric and Adolescent Diabetes (ISPAD). Summary of recommendations regarding COVID-19 in children with diabetes: keep calm and mind your diabetes care and public health advice. Pediatric Diab. 2020;21(3):413–4. https://doi.org/10.1111/pedi.13013.
[6] Raymond JK, Berget CL, Dricollo KA, Ketchum K, Cain C. “Fred” Thomas JF, GoVoT1 clinic: innovative telemedicine care model for young adults with type 1 diabetes. Diabetes Technol. Ther. 2016;18(6):385–90.
[7] Reid MW, Krishnan S, Berget C, Cain C, Thomas J, Klingensmith GJ, Raymond JK. GoVoT1 clinic: home telemedicine increases young adult engagement in diabetes care. Diabetes Technol. Ther. 2018;20(5):370–9.
[8] Wood CL, Clements SA, McFann K, Slover R, Thomas JF, Wadwa RP. Use of telemedicine to improve adherence to American diabetes association standards in pediatric type 1 diabetes. Diabetes Technol. Ther. 2018;18(1):7–14.
[9] Doger E, Bozbult R, Soysal A, Çakar E, Yenicer U, Akbas ED, Bideci A, Çamurdan O, Cinar P. Effect of telehealth system on glycemic control in children and adolescents with type 1 diabetes. JCPEN 2019;11(1):70–5.
[10] ISO 9241-11:1998(en), Ergonomic requirements for office work with visual display terminals (VDTs) — Part 11: Guidance on usability. https://www.iso.org/obp/ui/#iso:std:iso:9241:ed-1:v1:en (accessed Jul. 29, 2020).
[11] De Guzman KR, Snowwell CL, Taylor MLA, Sensanayake B, Haydon HM, Batch JA, Smith AC, Caflery L. A systematic review of pediatric telediabetes service models. Diabetes Technol. Ther. 2020;22(8):623–38.
[12] Parmanto B, Lewis Jr AN, Graham KM, Beretolet MH. Development of the telehealth usability questionnaire (TUQ). Int. J. Telehealth rehabilitation 2016;8(1):3–10. https://doi.org/10.5195/ijt.2016.6196.
[13] S. Hadhibai, J. Lacroix, and K. Lee, “Developing the first pan-Canadian acute care patient experiences survey,” Patient Experience Journal, vol. 5, no. 3, pp. 25–33, 2018 (accessed: Jul. 29, 2020).
[14] Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv. Health Sci. Educ. 2010;15(5):625–32. https://doi.org/10.1007/s10459-010-9222-4.
[15] UBC Clinical Research Ethics General Guidance Notes | Office of Research Ethics. https://ethicsresearch.ubc.ca/orc/ubc-clinical-research-ethics-general-guidance-notes (accessed Jul. 30, 2020).
[16] Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans – TCPS 2 (2018) – Chapter 2: Scope and Approach. https://ethics.gc.ca/eng/tcp2-epct2-2018-chapter2-chapter2.html (accessed Jul. 30, 2020).
[17] Alberta Innovates. (2017). ARECCI Ethics Guideline Tool. 2017. albertainnovates.ca/wp-content/uploads/2017/11/ARECCI-Ethics-Guideline-Tool.pdf (accessed Jul. 29, 2020).
[18] Pihoker C, Forsander G, Fantahun B, Virmanni A, Corathers S, Benitez-Aguirre P, Fu J, Maahas DM. ISPAD clinical practice guidelines 2018: the delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatr. Diabetes 2018;19:84–104.
[19] Fogel JL, Raymond JK. Implementing Telehealth in pediatric type 1 diabetes mellitus. Pediatr. Clin. North Am. 2020;67(4):661–4. https://doi.org/10.1016/j.pcl.2020.04.009.
[20] Schiaffini R, Barbetti F, Rapini N, Inzagi E, Deodati A, Patrera IP, Matteoli MG, Ciampalini P, Carducci C, Lorubbio A, Schiaffini G, Gianfarani S, School and pre-school children with type 1 diabetes during Covit-19 quarantine: the synergic effect of parental care and technology. Diabetes Res. Clin. Pract. 2020;166:108302. https://doi.org/10.1016/j.diabres.2020.108302.
[21] Peters AL, Garg SK. The Silver Lining to COVID-19: avoiding diabetic ketoacidosis admissions with telehealth. Diabetes Technol. Ther. 2020;22(6):449–53.
[22] F.S. Frielitz et al., Assessing the benefits and challenges of video consultations for diabetes care provision in the setting of the COVID-19 pandemic, and associated adaptation in care delivery, is essential in a time of such dramatic change. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank the families who participated in the survey, as well as the people who participated in survey review and development. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

AF, BH, MI, SA and SZ contributed to study design. AF and BH administered the survey. AA assisted with data collection and data linkage. AF, BH and MI performed data analysis. AF and BH prepared the manuscript. All authors participated in manuscript review and have approved the final version.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jetc.2020.100238.